Breast cancer: GE Healthcare wins pivotal FDA approval for 3D breast imaging

GE Healthcare wins FDA approval for its SenoClaire 3D breast tomosynthesis system, a device that could displace digital mammography as the major technology for breast cancer screening.

Imaging giant GE Healthcare (NYSE:GE) won FDA approval for its 3D breast tomosynthesis imaging system, MassDevice.com has learned.

GE Healthcare

News Well, Breast Cancer, Food & Drug Administration (FDA), Imaging, Pre-Market Approval (PMA)

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1rfJXwl